Under construction – not a live service
Sign in
Taking people in United StatesPhase 1

Tests azenosertib with chemotherapy or bevacizumab in ovarian cancer

Tests azenosertib with other cancer drugs in adults with ovarian cancer.

Key facts

Who runs it
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Where
Aurora, Boston, Durham, Houston, Nashville, New York, Providence, and St Louis, United StatesSee the 8 sitesAlso in 7 other countries, 27 sites
Registry title
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Status
Recruiting
Phase
Phase 1
People taking part
172 people, planned
Started
26 Oct 2020
Expected to end
30 Jun 2028
Type of study
Interventional, 5 groups
Treatments tested
  • Azenosertib
  • Carboplatin
  • Pegylated liposomal doxorubicin
  • Paclitaxel
  • Gemcitabine
  • Bevacizumab
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women with advanced high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer who have already had platinum chemotherapy.

Age
18 years or older
Sex
Women only
Disease stage
FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer. Part 1: the cancer must be platinum resistant (the platinum-free interval was less than 6 months) or platinum refractory.
Earlier treatment
Part 1: 1 or 2 earlier lines of treatment for advanced or metastatic disease, with at least one containing cisplatin or carboplatin. Part 2 dose escalation: 6 cycles of platinum-based doublet chemotherapy as the most recent treatment, with Complete Response, Partial Response or Stable Disease. Part 2 dose expansion: at least 4 cycles of platinum-based chemotherapy in 2L with Complete Response, Partial Response or Stable Disease, and the cancer got worse while on a PARP inhibitor given as 1L maintenance.

Main reasons for not taking part

  • Abdominal adenocarcinoma of unknown origin or a borderline ovarian tumor
  • Carcinosarcoma, even with a serous component
  • A serious illness or medical condition
  • Active second cancer that is uncontrolled, metastatic or needs treatment

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • For Part 1:
  • Histologically or cytologically confirmed FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma
  • Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the advanced or metastatic setting. At least one regimen must have contained cisplatin or carboplatin
  • The disease must be platinum resistant (ie, the PFI must have been < 6 months). Platinum refractory disease (ie, PD during first-line platinum-based therapy) is allowed; For Part 2 Dose Escalation:; Prior therapy:
  • Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy; Response to prior platinum therapy:
  • In the 1L setting: Complete Response, Partial Response, or Stable Disease to platinum-based chemotherapy
  • In the 2L setting:; Progressive Disease >183 days after receiving the last dose of platinum chemotherapy in the 1L setting,; Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy; Adequate hematologic, and organ function; For Part 2 Dose Expansion:
  • Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease
  • Subjects must have progressed while on a PARP inhibitor for 1L maintenance Additional protocol-defined inclusion criteria may apply

Who cannot take part

  • A serious illness or medical condition(s)
  • Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy; Additional protocol-defined exclusion criteria may apply
  • Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor
  • Subjects with carcinosarcomas (even if there is a serous component)

Where in United States

Also in 7 other countries, 27 sites

  • Aurora, ColoradoHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsNo longer taking part
  • Boston, MassachusettsHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people
  • Durham, North CarolinaHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people
  • Houston, TexasHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people
  • Nashville, TennesseeHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsNo longer taking part
  • New YorkHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people
  • Providence, Rhode IslandHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people
  • St Louis, MissouriHospital not named in the registryContact: K-Group, Beta, Inc., a subsidiary of Zentalis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

The 5 groups in the trial

  • Part 1: Azenosertib + carboplatinTreatment being tested

    Azenosertib in combination with carboplatin

    Treatment: Azenosertib and Carboplatin

  • Part 1: Azenosertib + PLDTreatment being tested

    Azenosertib in combination with pegylated liposomal doxorubicin (PLD)

    Treatment: Azenosertib and Pegylated liposomal doxorubicin

  • Part 1: Azenosertib + paclitaxelTreatment being tested

    Azenosertib in combination with paclitaxel

    Treatment: Azenosertib and Paclitaxel

  • Part 1: Azenosertib + gemcitabineTreatment being tested

    Azenosertib in combination with gemcitabine

    Treatment: Azenosertib and Gemcitabine

  • Part 2: Azenosertib + bevacizumabTreatment being tested

    Azenosertib in combination with bevacizumab

    Treatment: Azenosertib and Bevacizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer
Plain-language title
Tests azenosertib with chemotherapy or bevacizumab in ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026